Home > Boards > US Listed > Biotechs >

PULM (PULM)

PULM RSS Feed
Add PULM Price Alert      Hide Sticky   Hide Intro
Moderator: StocktraderDK, riskon
Search This Board: 
Last Post: 3/2/2021 7:03:30 AM - Followers: 79 - Board type: Free - Posts Today: 1

In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

 

What's Pulmatrix?

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

https://www.pulmatrix.com/isperse.html

iSPERSE uses proprietary cationic salt formulations to create a robust and flexible platform that can accommodate high drug loads and large drug molecules in highly dispersible particles, yielding superior drug delivery capabilities compared to conventional dry powder technologies that rely on the use of lactose blending or low-density particles. The properties of iSPERSE have meaningful therapeutic and patient benefits, including single formulations with multiple drugs, effective inhaled drug delivery to patients with normal or impaired lung function, and the use of simple and convenient inhaler devices with highly reproducible dosing. Pulmonary drug delivery offers several advantages for both local and systemic applications. Drug delivery via inhalation for local applications results in direct targeting to the site of action and minimization of systemic exposure and side effects. The advantages of pulmonary drug delivery for systemic applications can include: rapid onset of action, avoidance of first pass metabolism, and elimination of injection.

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

https://www.pulmatrix.com/news/iSPERSE_Fact_Sheet.pdf

iSPERSE powders are made via a straightforward, proven one- step spray drying process with high and consistent yields. A strong IP position on iSPERSE is being pursued through multiple patent applications, encompassing compositions, methods, and uses.

? Video demonstration of how iSPERSE works

 

https://www.pulmatrix.com/pipeline.html

About PUR3100

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

PUR3100 is engineered with iSPERSE™ to address the ongoing need for an acute treatment of migraine

PUR3100 is currently in pre-clinical investigation as an orally inhaled migraine therapy; Phase 1a and Phase 1b data anticipated in 2022

About Pulmazole

 

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

Pulmazole™ is the first inhaled antifungal candidate designed to overcome the limitations of oral antifungals and also potentially reduce steroid burden. It is currently in a Phase 2 trial forthe treatment of ABPA in patients with asthma.

Pulmatrix and Cipla intend to initiate a Phase 2b study designed with a longer treatment duration and key phase 3 enabling efficacy endpoints when the potential risk to both patient safety and to patient enrollment, presented by the ongoing COVID-19 pandemic, is reduced to an acceptable level for patients with this serious respiratory condition.

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

Cipla is India’s 2nd largest pharmaceutical company with global presence in over 130 countries, over 35 manufacturing facilities, and a vast network for direct commercialization and strategic alliances.

 

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

About PUR1800

PUR1800 is a Narrow Spectrum Kinase Inhibitor (NSKI) engineered with iSPERSE™ that is currently being investigated for the treatment of lung cancer. PUR1800 targets p38 MAP kinases (p38MAPK), Src kinases, and Syk kinases.17 These kinases play a critical role in chronicinflammation and airway remodeling.

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

 

https://www.pulmatrix.com/our-story.html#partnerships

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

 

"We look forward to 2021 as we plan to progress all of our programs. PUR1800 is planned to begin a clinical trial in early 2021, moving us closer to a potential licensing agreement with J&J for development and commercialization in lung cancer". From this article.

Johnson & Johnson is the world’s largest healthcare company with over 130,000 employees and 130 years of existence.

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

As you can see, their pipeline is quite impressive. What's even more impressive is the capability of this company to ink such big partnership deals with the biggest Pharma-giants in the sector. Remember this is a pennystock, so it's a huge confidence boost to see such interest in it. They also have an extremely solid management, of course, which I'm gonna link here: https://www.pulmatrix.com/leadership-management.html . Take a look at the Board of Directors: these guys are already in the game, leading other biopharma companies such as Kala Pharmaceuticals, Arena Pharmaceuticals. Nocion Therapeutics! https://www.pulmatrix.com/leadership-advisors.html

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

Pulmatrix recently had a DIRECT OFFERING https://finance.yahoo.com/news/pulmatrix-announces-40-million-registered-052400935.html **"**P. today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of 20,000,000 shares of the Company's common stock, at a purchase price of $2.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 16, 2021, subject to the satisfaction of customary closing conditions."

So yeah it's already closed, it was priced AT THE MARKET, it was a direct offering so institutions got in at 2$. No brainer right? At the current price, you have the chance to get in for a better one. But you know what's even more interesting? The offering was made for "healthcare-focused institutional investors"! This is the same bullish sign that I saw when Senseonics had its offering, seeing the interest in this company by healthcare experts made me add on the offering dips.

After this offering, they will have more than 70m in cash. They also receive royalties from partner Sensory Cloud upon sales of FEND, an OTC nasal hygiene product proven to reduce airborne respiratory droplets.

Check out their Q3 results, very promising and I'm looking forward for the Q4 ER https://finance.yahoo.com/news/pulmatrix-reports-third-quarter-2020-140000164.html

"As of September 30, 2020, Pulmatrix had $34.5 million in cash compared to $23.4 million as of December 31, 2019. Pulmatrix generated $4.4 million of revenue in the third quarter of 2020compared to $1.4 million in the third quarter of 2019. The revenue for the second quarter of 2020 was the result of the collaboration and licensing agreements with Cipla and JJEI, respectively. Research and development expenses for the third quarter of 2020 and 2019 were $3.9 million and $3.3 million, respectively. Included in the third quarter 2020 costs were pre-clinical toxicology and Chemistry, Manufacturing and Controls costs for the PUR1800 program and clinical study costs incurred for the Phase 2 Pulmazole study. General and administrative expenses for the third quarter of 2020 and 2019 were $1.8 million. Included in the third quarter 2020 costs were general operating expenses such as employment, lab and office lease, legal, patent and audit fees. Net loss was $10.6 million for the third quarter of 2020 and $3.6 million for the third quarter of 2019. The net loss for the third quarter 2020 was primarily due to warrant inducement expense of $9.3 million and manufacturing costs for the upcoming PUR1800 Phase 1b clinical study and the recently terminated Pulmazole Phase 2 study. The net loss for the third quarter of 2019 was due to spend on the Pulmazole Phase 2 study."

About institutional ownership: https://fintel.io/so/us/pulm Go onto the website, you'll see that in the last weeks institutions piled in, from Vanguard to BlackRock to Renaissance Technologies.

r/pennystocks - In-Depth DD on $PULM biopharma pennystock partnering with giants like Johnson&Johnson, Cipla

 

https://www.wsj.com/market-data/quotes/PULM/research-ratings

https://www.wallstreetzen.com/stocks/us/nasdaq/pulm/stock-forecast

https://money.cnn.com/quote/forecast/forecast.html?symb=PULM

There's currently a BUY rating and a 10$ price target, at least from what I've gathered online looking through various sources. We should probably expect news soon.

 

PULM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PULM News: Statement of Ownership (sc 13g) 02/24/2021 10:23:04 AM
PULM News: Small Company Offering and Sale of Securities Without Registration (d) 02/23/2021 04:21:20 PM
PULM News: Current Report Filing (8-k) 02/16/2021 04:36:40 PM
PULM News: Pulmatrix closes $40M capital raise 02/16/2021 01:35:18 PM
PULM News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 10:06:03 AM
PostSubject
#3089  Sticky Note A very rare situation here imo, we have: riskon 09/22/20 05:49:31 PM
#3321   Lets avoid the gap Open and run.... would europtiger 03/02/21 07:03:30 AM
#3320   Or I guess you could say -- that's riskon 03/01/21 11:33:30 PM
#3319   Well obviously, they have warrants. I don't riskon 03/01/21 11:32:13 PM
#3318   H.C. Wainwright Maintains Their Buy Rating on Pulmatrix (PULM) https://www.anal StocktraderDK 03/01/21 03:28:31 PM
#3317   Expecting this to go from zero to hero riskon 03/01/21 03:09:05 PM
#3316   Some volume coming in europtiger 03/01/21 03:08:22 PM
#3315   Definitely sale prices. It will turn quickly riskon 03/01/21 01:34:27 PM
#3314   PULM is a long term hold. Cost of StocktraderDK 03/01/21 01:30:26 PM
#3313   PULM : Financial Due Diligence Preface: I am NOT StocktraderDK 03/01/21 01:28:43 PM
#3312   Solid DD on PULM https://www.reddit.com/r/PULM/comments/lsosy1/solid_dd_on_pulm StocktraderDK 03/01/21 01:25:40 PM
#3311   Info on all big buyers this month including StocktraderDK 03/01/21 01:23:03 PM
#3310   $10 https://www.analystratings.com/articles/h-c-wainwright-maintains-their-buy- StocktraderDK 03/01/21 01:22:11 PM
#3309   SALE ON PULM TODAY! ONLY: 1.48-1.54 - GREAT StocktraderDK 03/01/21 01:21:54 PM
#3308   Next Breath Charitable Organization Created -- 2/25/2021 riskon 02/28/21 10:58:28 PM
#3307   Added om dip again today $PULM StocktraderDK 02/26/21 12:56:38 PM
#3306   PUR1900 US ABPA market worth $8B in market riskon 02/25/21 01:44:48 PM
#3305   Thats a marketcap 8 Billion plus hmmmmm europtiger 02/25/21 12:52:51 PM
#3304   When your motto is "Changing medicine with a riskon 02/25/21 12:18:15 PM
#3303   $PULM Catalysts: (non-exhaustive) riskon 02/24/21 05:47:56 PM
#3302   Added more shares @ 1.67 StocktraderDK 02/24/21 03:46:32 PM
#3301   We will move DOLLARs, in a hurry. riskon 02/24/21 12:54:01 PM
#3300   Have a feeling we ready to Go After europtiger 02/24/21 11:43:37 AM
#3299   When they all got there shares.... run! europtiger 02/24/21 10:46:27 AM
#3298   Nocion Therapeutics ?? riskon 02/24/21 10:40:53 AM
#3297   PUR3100 Details (Cipla) ?? riskon 02/24/21 10:40:38 AM
#3296   So many good news waiting to come, just StocktraderDK 02/24/21 10:39:19 AM
#3295   PUR1900 FDA Type C Results, LPAD / EUA ??? riskon 02/24/21 10:33:58 AM
#3294   FEND Government Contracts ?? riskon 02/24/21 10:33:33 AM
#3293   PUR1800 Repurposed ?? riskon 02/24/21 10:22:33 AM
#3292   PUR1900 Reformulations / Combinations ?? riskon 02/24/21 10:22:06 AM
#3291   Nob Hill Therapeutics ?? riskon 02/24/21 10:21:31 AM
#3290   Siwa Therapeutics ?? riskon 02/24/21 10:21:16 AM
#3289   ohh what a coincidence anyway it is good StocktraderDK 02/24/21 09:50:40 AM
#3288   Yes it was discussed on stock twits yesterday alwaysliquid 02/24/21 09:39:00 AM
#3287   No I did not see that, but I StocktraderDK 02/24/21 09:37:04 AM
#3286   Thank you stock trader dk for updating this alwaysliquid 02/24/21 09:19:54 AM
#3285   We will move fast soon... StocktraderDK 02/24/21 09:06:21 AM
#3284   This was apart of the 20M share/$40M direct riskon 02/24/21 09:02:34 AM
#3283   Represents warrants to purchase up to 1,300,000 shares StocktraderDK 02/24/21 07:26:12 AM
#3282   Added some DD in the IBOX. StocktraderDK 02/23/21 04:51:03 PM
#3281   Most direct offerings have warrants attached. This riskon 02/23/21 04:47:50 PM
#3280   Pulmatrix recently had a DIRECT OFFERING https://finance.yahoo.com/news/pulmatri StocktraderDK 02/23/21 04:42:18 PM
#3279   $PULM is a long term hold. Cost of StocktraderDK 02/23/21 04:35:08 PM
#3278   Nothing JnJ related was discussed during this JnJ Webinar. riskon 02/23/21 01:02:01 PM
#3277   Ok thx for the info europtiger 02/23/21 11:36:08 AM
#3276   Doesn't look like iSPERSE is going to be riskon 02/23/21 11:35:37 AM
#3275   Aye -- looks like Barda is interested in riskon 02/23/21 11:17:40 AM
#3274   Really strong return wo far Webinar starting now europtiger 02/23/21 10:59:38 AM
#3273   All the ask slapping goes just a tick europtiger 02/23/21 10:12:40 AM
#3272   Yeah lets Hope we do hear something europtiger 02/23/21 09:59:09 AM
PostSubject
Consent Preferences